Lexatumumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Lexatumumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetTRAIL-R2
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6346H9832N1720O2002S42
Molar mass143.6 kg/mol g·mol−1
 ☒N☑Y (what is this?)  (verify)

Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2), intended for the treatment of cancer.[1]

HGS-ETR2 antibodies were generated by HGS through a collaboration with Cambridge Antibody Technology.[2]

Development was discontinued in 2015.[3]

References[edit]

  1. ^ Statement on a Nonproprietary Name adopted by the USAN Council - Lexatumumab, American Medical Association.
  2. ^ "Archived copy". Archived from the original on 2008-05-16. Retrieved 2010-05-12.CS1 maint: Archived copy as title (link)
  3. ^ "Lexatumumab - AdisInsight". adisinsight.springer.com.